[go: up one dir, main page]

MX2015011802A - Rifaximina para usarse en el tratamiento de infecciones vaginales. - Google Patents

Rifaximina para usarse en el tratamiento de infecciones vaginales.

Info

Publication number
MX2015011802A
MX2015011802A MX2015011802A MX2015011802A MX2015011802A MX 2015011802 A MX2015011802 A MX 2015011802A MX 2015011802 A MX2015011802 A MX 2015011802A MX 2015011802 A MX2015011802 A MX 2015011802A MX 2015011802 A MX2015011802 A MX 2015011802A
Authority
MX
Mexico
Prior art keywords
rifaximin
reaction vessel
relates
bacteria
vaginal infections
Prior art date
Application number
MX2015011802A
Other languages
English (en)
Inventor
Giuseppe Claudio Viscomi
Fiorella Calanni
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Publication of MX2015011802A publication Critical patent/MX2015011802A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se relaciona con rifaximina para usarse en el tratamiento de infecciones vaginales bacterianas; la invención también se relaciona con el uso para tratar infecciones caracterizadas por la presencia de bacterias que puedan ser resistentes a la clindamicina y/o metronidazol; la invención también se relaciona con el uso de rifaximina para tratar pacientes con infecciones vaginales que han recaído después de un tratamiento previo o que tienen bacterias resistentes a antibióticos diferentes a la rifaximina.
MX2015011802A 2013-03-15 2014-03-03 Rifaximina para usarse en el tratamiento de infecciones vaginales. MX2015011802A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361794323P 2013-03-15 2013-03-15
PCT/IB2014/059400 WO2014140988A1 (en) 2013-03-15 2014-03-03 Rifaximin for use in the treating of vaginal infections.

Publications (1)

Publication Number Publication Date
MX2015011802A true MX2015011802A (es) 2016-01-08

Family

ID=50382507

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011802A MX2015011802A (es) 2013-03-15 2014-03-03 Rifaximina para usarse en el tratamiento de infecciones vaginales.

Country Status (11)

Country Link
US (1) US20160038468A1 (es)
EP (1) EP2968283A1 (es)
JP (1) JP2016510809A (es)
KR (1) KR20150129691A (es)
CN (1) CN105142636A (es)
AU (1) AU2014229467A1 (es)
CA (1) CA2897758A1 (es)
EA (1) EA201591267A1 (es)
MX (1) MX2015011802A (es)
TN (1) TN2015000409A1 (es)
WO (1) WO2014140988A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106860451A (zh) * 2017-02-28 2017-06-20 丹诺医药(苏州）有限公司 一种利福霉素‑硝基咪唑偶联分子的新应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
IT1253711B (it) 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
US5166959A (en) 1991-12-19 1992-11-24 Hewlett-Packard Company Picosecond event timer
US7923553B2 (en) 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
PL1698630T3 (pl) 2005-03-03 2014-12-31 Alfasigma Spa Nowe postacie polimorficzne rifaksyminy,sposoby ich wytwarzania i ich zastosowanie w preparatach leczniczych
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
EP2069363B1 (en) 2006-09-22 2013-03-20 Cipla Ltd. Rifaximin in an amorphous form
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
EP2257557A4 (en) 2008-02-25 2011-06-29 Salix Pharmaceuticals Ltd FORMS OF RIFAXIMINE AND APPLICATIONS THEREOF
EA022490B1 (ru) 2010-06-03 2016-01-29 Саликс Фармасьютикалс, Лтд. Новые формы рифаксимина и их применение
CA2802874A1 (en) 2010-06-16 2011-12-22 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
WO2012076832A1 (en) * 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) * 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.

Also Published As

Publication number Publication date
CN105142636A (zh) 2015-12-09
AU2014229467A1 (en) 2015-08-06
JP2016510809A (ja) 2016-04-11
EP2968283A1 (en) 2016-01-20
KR20150129691A (ko) 2015-11-20
TN2015000409A1 (en) 2017-01-03
CA2897758A1 (en) 2014-09-18
WO2014140988A1 (en) 2014-09-18
US20160038468A1 (en) 2016-02-11
EA201591267A1 (ru) 2016-03-31

Similar Documents

Publication Publication Date Title
MX2019008550A (es) Metodos y sistemas para tratamiento de oxido de etileno.
SA520411108B1 (ar) مركبات حلقية كبيرة واستخداماتها
MX2020012560A (es) Metodos para tratar infecciones por el virus de filoviridae.
WO2018183888A3 (en) Methods of treating t cell exhaustion by inhibiting or modulating t cell receptor signaling
MX2016014807A (es) Singenes de alfa(1,2)fucosiltransferasa para su utilizacion en la produccion de oligosacaridos fucosilados.
MX2022005304A (es) Mutaciones de la enzima crispr que reducen los efectos fuera del blanco.
PH12018501378A1 (en) Compositions and methods for the treatment of hemoglobinopathies
MX2023004221A (es) Inhibidores de rad51.
CA2946050A1 (en) Ammonia-oxidizing nitrosomonas eutropha strain d23
BR112017005827A2 (pt) dispersão coloidal, método de fazer uma dispersão coloidal e catalisador
MX2015011704A (es) Composicion de recubrimiento, pelicula que contiene la misma y metodo para formar una pelicula sellable.
AU2016246521A8 (en) Treatment of lung cancer with inhibitors of glutaminase
MY173782A (en) Ethylene polymerization process using an inhibitor
BR112017000941A2 (pt) chapa de aço elétrica não orientada que tem excelentes propriedades magnéticas
MX2015011802A (es) Rifaximina para usarse en el tratamiento de infecciones vaginales.
MX2016016709A (es) Proceso para preparar polimeros basados en etileno que usa una distribucion de monoxido de carbono.
MX2019003493A (es) Proceso para la fabricacion de polietileno.
BR112015019404A2 (pt) polímeros de vinila preparados através de polimerização de suspensão e métodos dos mesmos
AU2016323967A8 (en) Compositions and methods for the treatment and prevention of radiation dermatitis
MX2024015154A (es) Composiciones y metodos para floculacion
JOP20200111A1 (ar) تحضير حمض الفوسفوريك
SA521421684B1 (ar) تشتيت بوليمر بواسطة بلمرة جذرية متحكم فيها
WO2013025467A3 (en) Methods of treating hematological proliferative disorders by targeting epha3 expressed on aberrant vasculature in bone marrow
PH12017500149A1 (en) Hair products containing polyetheramine
MX2014009861A (es) Red de aireacion de flujo cerrado.